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Abstract A growing body of evidence suggests that the
efficacy of cytokines in cancer therapy can be increased by
targeting strategies based on conjugation with ligands that
recognize receptors expressed by tumor cells or elements
of the tumor microenvironment, including the tumor vas-
culature. The targeting approach is generally conceived to
permit administration of low, yet pharmacologically active,
doses of drugs, thereby avoiding toxic reactions. However,
it is becoming clear that, in the case of cytokines, this
strategy has another inherent advantage, i.e. the possibility
of administering extremely low doses that do not activate
systemic counter-regulatory mechanisms, which may limit
their potential therapeutic effects. This review is focused
on the use of tumor vasculature-homing peptides as vehi-
cles for targeted delivery of cytokines to tumor blood
vessel. In particular, we provide an overview of peptide-
cytokine conjugates made with peptides containing the
NGR, RGD, isoDGR or RGR sequences and describe, in
more details, the biological and pharmacological properties
of NGR-hTNF, a peptide-tumor necrosis factor-a conju-
gate that is currently being tested in phase II and III clinical
studies. The results of preclinical and clinical studies per-
formed with these products suggest that peptide-mediated
vascular-targeting is indeed a viable strategy for delivering
bioactive amounts of cytokines to tumor endothelial cells
without causing the activation of counter-regulatory
mechanisms and toxic reactions.
1 Introduction
The efficacy of cytokines in cancer therapy is often limited
by systemic toxicity and counter-regulatory mechanisms.
Recent studies suggest that these limitations can be over-
come by targeting strategies based on the conjugation of
these proteins with ligands capable of delivering them to
the tumor site, thereby allowing administration of lower
doses and reducing systemic effects [1, 2]. Among the
various approaches that have been developed, cytokine
conjugation or fusion with antibodies or peptide ligands
capable of recognizing specific receptors in tumor tissues
are the most advanced. These ligands typically recognize
receptors expressed by tumor cells or elements of the tumor
microenvironment, including the tumor vasculature [1]. A
comprehensive database of most tumor-homing peptides so
far developed and their receptors has been recently repor-
ted [3]. Remarkably, a large proportion of these peptides
have some common motifs, such as NGR and RGD [3].
This review is focused on the application of peptides
containing these or other motifs as ligands for targeting
tumor vessels with cytokines capable of altering the
physiology of endothelial cells and tumor microenviron-
ment, and, consequently, capable of promoting the tumor
penetration of antitumor drugs, enhancing the infiltration of
immune cells and inhibiting tumor growth. As a prototypic
example of this class of molecules, we describe, in more
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detail, the biological and pharmacological properties of
NGR-hTNF, a peptide-tumor necrosis factor (TNF)-a
conjugate originally developed by our group, which is
currently being tested in phase II and III clinical studies. In
addition, we provide an overview of the various peptide-
based delivery systems containing the NGR, RGD, isoDGR
or RGR sequences that have been exploited for the delivery
of TNF and other cytokines, such as interferon (IFN)-c and
IFNa2a, to tumor vessels.
2 The NGR-Mediated Targeting of Cytokines to Tumor
Vasculature
2.1 The NGR Motif
The NGR motif was discovered in the 1990s by in vivo
selection of peptide-phage libraries in tumor-bearing mice
[4]. Systemic administration of a phage library into nude
mice bearing human breast carcinoma xenografts led to the
selection of tumor vasculature-homing phages carrying
various peptide sequences containing this motif. Mecha-
nistic studies showed that NGR can specifically recognize
vessels expressing aminopeptidase N (CD13), a mem-
brane-bound metalloproteinase that is barely or not at all
expressed by normal blood vessels, but is up-regulated in
angiogenic blood vessels [5–8]. This protease has a role in
protein degradation, cytokine regulation, antigen presen-
tation, cell proliferation, cell migration, and angiogenesis
[9–11]. In tumor tissues, CD13 is expressed by endothelial
cells and pericytes, and, in some cases, by tumor cells and
fibroblasts. CD13 is also expressed by many cells of nor-
mal tissues, including epithelial cells from the small
intestine, proximal renal tubules, prostate, bile duct cana-
liculi, keratinocytes, mast cells, myeloid cells, and antigen-
presenting cells [12–15]. Immunohistochemical and bio-
distribution studies showed that CNGRC-containing com-
pounds bind CD13-positive tumor blood vessels, but not
other CD13-rich tissues [6, 16]. The structural basis of this
NGR selectivity is still unknown. The recognition of
angiogenic blood vessels by NGR has also been demon-
strated with cyclic-NGR-labeled paramagnetic quantum
dots and quantitative molecular magnetic resonance
imaging (MRI) in tumor mouse models [17]. Ex vivo two-
photon laser scanning microscopy showed that these par-
ticles bind primarily to the endothelial lining of tumor
vessels.
Peptides containing the NGR sequence have been used
by several investigators for delivering a variety of different
compounds to tumor blood vessels, including chemother-
apeutic drugs, liposomes, anti-angiogenic compounds,
DNA complexes, viral particles, fluorescent compounds,
contrast agents, and other biological response modifiers.
The stability and immunogenicity of NGR peptides and the
pharmacological properties of these compounds have
recently been reviewed [18]. NGR peptides have also been
fused to cytokines, such as TNF, IFNc and IFNa2a, in an
attempt to improve their therapeutic index. These com-
pounds will be described with more detail in the following
sections.
2.2 The NGR-TNF Example
2.2.1 Historical Background and Rationale for the TNF
Vascular Targeting Approach
The discovery of TNF in 1975 as an endotoxin-induced
serum protein capable of causing hemorrhagic necrosis of
tumors in mice [19, 20] led to an explosion of basic and
translational research aimed at exploiting its potential anti-
tumor activity in cancer patients. This research led, in the
mid-1980s, to the identification of the TNF gene and to the
production of recombinant TNF in Escherichia coli cells
for clinical trials. Unfortunately, despite the impressive
anti-tumor effects observed in animal models, phase I–II
clinical trials, carried out few years later, showed that TNF
induces toxic effects and no, or very low, anti-tumor
responses when administered systemically to patients [21,
22]. Attempts were made, therefore, to prepare less toxic
TNF mutants and to increase its efficacy by combining it
with other drugs or cytokines or by manipulating its half-
life in the circulation [23, 24]. Although these strategies did
not meet initial expectations, later studies, reported in the
early 1990s, showed that the loco-regional administration
of high-dose TNF in combination with chemotherapeutic
drugs induces high response rates in patients with mela-
noma or sarcoma of the extremities [25–28]. These results,
which led to the registration of TNF as a drug for loco-
regional treatments of sarcomas confined to the limbs, are
of outstanding relevance because they show that the anti-
tumor effects of TNF can be successfully exploited in
patients if sufficient dose levels are attained locally. These
findings prompted further studies aimed at developing
ligand-directed delivery systems, in an attempt to achieve
high local concentrations of TNF through systemic
administration of low, non-toxic doses of targeted TNF.
Using an antibody-avidin-based targeting system, we
demonstrated, in the mid 1990s, that a significant increase
of anti-tumor activity of TNF can be achieved in animal
models by pre-targeting tumors with a biotin-antibody
conjugate specific for a tumor cell surface antigen, fol-
lowed by administration of avidin and biotinylated TNF
[29, 30]. Although this ‘three-step’ targeting approach was
not further developed for clinical studies, owing to its
complexity, the good results obtained in animal models
suggested that targeted delivery of TNF to tumors might
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indeed represent a valuable strategy for increasing its
therapeutic index. Notably, in these studies, targeted TNF
could affect well established and vascularized tumors, but
not avascular, freshly transplanted tumors [29]. Further-
more, we showed that bioactive TNF could dissociate from
the targeted tumor cells and reach endothelial cells in the
tumor microenvironment, thereby causing vascular damage
and tumor tissue necrosis [31].
These findings provided the rationale for developing
other targeting systems capable of directly delivering TNF
to tumor vessels. For this purpose, TNF was fused to
CNGRCG, a peptide capable of selectively recognizing
targets expressed by angiogenic vessels and therefore to
‘home’ to the tumor vasculature [4, 16]. Based on prom-
ising results obtained in preclinical studies, this fusion
protein, which has been generated and studied at the San
Raffaele Scientific Institute and called NGR-TNF, was out-
licensed to Molmed SpA. The biochemical properties of
this drug and the results of preclinical and clinical phase I,
II, and III studies are reviewed in the following sections.
2.2.2 The NGR-TNF Receptors
As the NGR-TNF fusion protein is made by two functional
domains (NGR peptide and TNF), the receptor system of
this conjugate includes receptors for both ligands, i.e.
CD13 and TNF receptors. The role of CD13 as a receptor
for NGR peptides has been discussed above. Regarding
TNF receptors, it is important to keep in mind that soluble
bioactive TNF is a homotrimeric protein capable of inter-
acting with two distinct cell surface receptors of 55–60 and
75–80 kDa, respectively (TNF-R1 and TNF-R2) [32].
TNF-R1 is thought to mediate most TNF effects, whereas
TNF-R2, owing to its higher affinity and rapid dissociation
rate, plays a role in increasing the local concentration of
TNF and passing it to TNF-R1 [33–36]. TNF-R2 also
contributes to several cellular responses by direct signaling
upon TNF-mediated clustering [37–40]. Notably, human
TNF can efficiently bind murine TNF-R1, but it cannot
bind murine TNF-R2, because of species-specificity of this
interaction [41]. For this reason, murine NGR-TNF (NGR-
mTNF) has been used in preclinical studies in mice and
human NGR-TNF (NGR-hTNF) in clinical studies in
patients. Structure-activity and receptor-binding studies
performed with both products, prepared by recombinant
DNA technology, showed that CNGRCG peptide does not
prevent folding, oligomerization, and binding of the TNF
domain to TNF-R1 and TNF-R2 [16]. On the other hand,
the TNF subunits do not prevent the interaction of
CNGRCG with the CD13 receptor. As a consequence,
NGR-TNF may undertake multivalent high-avidity inter-
actions with both TNF and CD13 receptors on cells that
express both receptor types [16]. While TNF receptors are
unlikely to provide selectivity for tumor vessels, being
expressed by most normal cells, CD13 binding is likely the
major mechanism for tumor vessel selectivity when low
doses of NGR-TNF are administered. In fact, tumor ves-
sels, but not other CD13-expressing tissues, express a
functionally active form of CD13 that binds NGR-TNF [6].
2.2.3 Anti-Tumor Activity of NGR-TNF in Animal Models
Early preclinical studies performed in murine RMA lym-
phoma or B16F1 melanoma models showed that systemi-
cally administered NGR-TNF was more active and less
toxic than TNF [16]. The dose-response curve of NGR-
TNF was wider and more complex than that of TNF [42]:
while microgram doses of TNF were necessary to induce
anti-tumor effects, a wider range of NGR-TNF doses (from
picograms to micrograms) exerted anti-tumor effects in
these models (see Fig. 1a). Interestingly, intermediate
doses of NGR-TNF (3–10 ng) were paradoxically less
active than picogram doses. Mechanistic studies showed
that NGR-TNF and TNF, when injected at doses greater
than 1 ng, could induce the shedding in circulation of
soluble TNF receptors, which can act as TNF inhibitors
[42]. This counter-regulatory mechanism can be over-
whelmed by the administration of microgram doses, lead-
ing to anti-tumor effects and, for the same reason, also to
systemic toxicity. Interestingly, low doses of NGR-TNF or
TNF (in the picogram range) did not activate soluble
receptor shedding (Fig. 1b), likely because of insufficient
interaction with endothelial cells in normal vessels [42].
However, in this case, only NGR-TNF could exert phar-
macological effects, likely owing to high-avidity interac-
tion with TNF-Rs and CD13 on tumor vessels [6, 15] (see
Fig. 1c for a schematic representation of this concept).
Thus, the vascular targeting strategy can be exploited, in
the case of TNF, to avoid not only toxic reactions but also
negative feedback mechanisms, provided that very low
doses of targeted TNF are used.
Studies on the mechanism of action showed that low-dose
NGR-TNF (0.1 ng/mouse) is sufficient to induce apoptosis
of endothelial cells and, at later time points, tumor cell
apoptosis, likely as a consequence of vascular damage [43].
This effect was markedly increased when NGR-TNF was
combined with low doses of endothelial-monocyte-activat-
ing polypeptide II (EMAP-II), a tumor-derived anti-angio-
genic cytokine that sensitizes the tumor vasculature to the
damaging activity of TNF [43]. However, when NGR-TNF
was used alone, marked vascular occlusion was observed
only with high doses (e.g. 10 lg) but not, or much less, with
the low dose (0.1 ng), suggesting that different doses can
trigger different anti-tumor mechanisms [44]. Thus, other
mechanisms are likely brought into play by low-dose NGR-
TNF to delay tumor growth. A recent study showed that
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administration of low-dose NGR-TNF to tumor-bearing
mice induces the up-regulation VCAM-1 and ICAM-2 in
endothelial cells and the release of several cytokines/che-
mokines involved in T-cell activation and migration, such as
MCP-1/CCL-2, MCP-3/CCL-7, MIP-2, oncostatin-M, and
stem cell factor (SCF), in tumors [45], suggesting that
inflammatory/immune responses might contribute to the
activity of NGR-TNF.
2.2.4 Anti-Tumor Activity of NGR-TNF in Combination
with Chemotherapy in Animal Models
High-dose TNF exerts synergistic effects with melphalan
or doxorubicin in patients treated by regional isolated limb
perfusion [25–28]. Remarkably, low-dose NGR-TNF
(0.1 ng/mouse, six orders of magnitude lower than the
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enhance the anti-tumor activity of melphalan and doxoru-
bicin in murine models, with no evidence of toxicity [42].
Low-dose NGR-TNF could also enhance the response to
other drugs, including cisplatin, gemcitabine, and paclit-
axel in various transplantable tumor models and in the
orthotopic TRAMP model of prostate cancer, with no
evidence of increased toxicity [44, 46]. The optimal
administration schedule for maximal synergism required a
2-h delay between the administration of NGR-TNF and
chemotherapeutic drugs, irrespective of drug and tumor
model used. It is well known that TNF can rapidly increase
endothelial permeability and decrease the interstitial fluid
pressure in tumors, both representing important barriers
that limit drug penetration [26, 47–54]. These mechanisms
may increase the convective transport of drugs through
tumor vessel walls and interstitium, eventually leading to
increased drug uptake by tumor cells. MRI studies per-
formed with mice bearing subcutaneous lymphomas
showed a greater leakage of ultra-small iron oxide particles
(USPIO) from the vasculature to the interstitial area after
treatment with NGR-TNF, than with TNF [55]. Further-
more, pre-administration of low-dose NGR-TNF to mice
increased the tumor uptake of doxorubicin (administered
2 h later) in murine melanoma and lymphoma models [42].
These findings support the concept that NGR-TNF can
indeed increase drug uptake by increasing the leakiness of
tumor vessels, at least in those areas characterized by poor
perfusion and low permeability. It appears, therefore, that
low-dose NGR-TNF has distinct vascular effects, causing
early activation of endothelial cells (after 1–2 h) and
consequent barrier alteration and expression of leukocyte
adhesion molecules, followed by apoptosis of endothelial
cells 8–24 h later [43]. Interestingly, chromogranin A, a
protein capable of inhibiting the vascular leakage induced
by TNF [56], could inhibit the synergism between NGR-
TNF and chemotherapy in murine models [57]. Synergism
between low-dose NGR-TNF and doxorubicin was
observed in immunocompetent mice but not in nude or
IFNc-knockout mice, pointing to a crucial role for locally
produced IFNc in mediating the overall antitumor effects
[58].
2.2.5 Anti-Tumor Activity of NGR-TNF in Combination
with Immunotherapy in Animal Models
A recent study showed that low-dose NGR-TNF (0.1 ng)
promotes lymphocyte extravasation in tumors [45].
Mechanistic studies showed that NGR-TNF, besides up-
regulating leukocyte adhesion molecules on tumor vessels,
can induce the release of various chemokines in tumor
tissues (mentioned above). These mechanisms associate
with increased tumor infiltration of endogenous or adop-
tively transferred cytotoxic T lymphocytes in transplanta-
ble models of melanoma and in the TRAMP model of
spontaneous prostate cancer [45]. Remarkably, NGR-TNF
did not modify T-cell distribution in the blood, spleen, or
kidney of tumor-bearing mice. The combination of NGR-
TNF and adoptive immunotherapy increased the overall
survival of tumor-bearing mice, with no evidence of toxic
reactions. NGR-TNF could also increase the efficacy of
active immunotherapy (vaccination) either alone or in
combination with chemotherapy [45]. In all the experi-
mental conditions tested, a comparable dose of TNF was
marginally or not active, supporting the hypothesis that
peptide-mediated targeted delivery of TNF to tumor ves-
sels was crucial for the activity.
2.2.6 Clinical Studies with NGR-hTNF in Patients
with Solid Tumors
Various phase I and II studies have been performed with
NGR-hTNF in patients with solid tumors, both as a single
agent and in combination with chemotherapy.
NGR-hTNF as a single agent The first phase I study (EO-
RTC 16041) was aimed at investigating dose-limiting toxic-
ities, maximum tolerated dose (MTD), pharmacokinetics,
pharmacodynamics, and vascular response in solid tumors
[59]. Escalating doses (0.2–60 lg/m2) of NGR-hTNF were
administered to 69 patients once every 3 weeks via a 20 or
60 min infusion rate (intravenously). NGR-TNF was well
tolerated (MTD: 45 lg/m2 administered in 1 h). Chills and
fever were the most frequently observed toxicities. The mean
apparent terminal half-life ranged from about 1 to 2 h.
Dynamic contrast-enhanced MRI (DCE-MRI) showed a
Fig. 1 Effect of NGR-TNF and TNF on tumor growth and soluble TNF
receptor shedding, an important counter-regulatory mechanism. a Effect
on the growth of RMA-T lymphomas implanted subcutaneously in mice
(tumor volumes, 4 days after treatment, showing different dose-response
curves for NGR-TNF and TNF) [42]. b Effect of low (0.1 ng/mouse),
moderate (10 ng), and high (1,000 ng) doses of NGR-TNF or TNF on the
shedding of soluble TNF-R2 (serum levels, 1 h after treatment). Strong
activation of this counter-regulatory mechanism occurs only with
moderate and high doses of both cytokines. c Schematic representation
of the hypothetical interactions of low, moderate, and high doses of NGR-
TNF or TNF with soluble and membrane TNF receptors in normal
(CD13-negative) and tumor-associated vessels (CD13-positive). This
model can explain the different anti-tumor dose-response curves
observed (adapted from [42]). According to this model, moderate doses
of NGR-TNF or TNF (e.g. 10 ng/mouse), can efficiently interact with
membrane TNF receptors throughout the body and trigger the systemic
release of sTNF-Rs, which act as potent TNF inhibitors. High doses of
both cytokines (e.g. 1,000–10,000 ng) can saturate the circulating sTNF-
Rs, thereby leaving a significant amount of bioactive TNF free to interact
with membrane receptors in neoplastic and normal tissues and to induce,
therefore, anti-tumor as well as toxic effects. In contrast, low-dose NGR-
TNF or TNF (e.g. 0.1 ng) cannot induce massive soluble receptor
shedding, likely because of insufficient interaction with endothelial cells
in normal vessels. However, in this case, NGR-TNF can still induce anti-
tumor effects owing to high-avidity interaction with membrane TNF
receptors and CD13 on tumor vessels. TNF tumour necrosis factor
b
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vascular response to NGR-hTNF [59]. No objective responses
were observed, but 39 % of patients had stable disease, with a
median duration of 3 months [59]. In another phase I study,
performed in 31 patients with advanced solid cancer, DCE-
MRI showed larger anti-vascular effects of NGR-hTNF in
smaller tumors, which have less mature neovasculature [60].
No patients developed anti-NGR-TNF antibodies during
treatment. The circulating levels of soluble TNF receptors
increased in a dose-proportional manner, but only at doses
greater than 1.3 lg/m2. As preclinical studies showed that
soluble receptors shedding in circulation can lead to a bell-
shaped dose-response curve, another phase I study was
designed to define the optimal biological dose of NGR-hTNF
in the low-dose range (0.2–1.6 lg/m2, 1 h infusion) [61].
Based on soluble receptor kinetics, tolerability, anti-vascular
effects, and disease control (44 % stable diseases for a median
time of 5.9 months were observed), the dose of 0.8 lg/m2 of
NGR-hTNF was chosen for subsequent studies, either alone or
with standard chemotherapy.
Single-agent phase II studies with low-dose NGR-TNF
(0.8 lg/m2, 1 h infusion, every 3 weeks or weekly) were
conducted in malignant pleural mesothelioma (MPM),
hepatocellular carcinoma (HCC), and colorectal cancer
(CRC) [62–64]. These studies showed radiological anti-
vascular effects and significant disease control with low-
dose NGR-hTNF. The study in MPM patients showed
disease control in about half of 57 previously treated
patients, which was maintained in the tri-weekly cohort for
4.4 months and for 9.1 months in the weekly cohort [62].
In the overall study population, the observed median sur-
vival was 12.1 months. NGR-hTNF was well tolerated in
both cohorts. In the three-weekly cohort (n = 43), common
grades 1 and 2 short-lived chills (71 %) and one grade 3
drug-related toxicity were observed [62]. These results are
remarkable considering that, currently, there are no stan-
dard options for patients with MPM who are failing a front-
line pemetrexed-based regimen and considering the easily
manageable toxicity profile of NGR-TNF.
In the study in patients with HCC, NGR-hTNF was
administered to 27 previously treated patients with
advanced-stage disease [63]. One complete response,
maintained after 20 months in a sorafenib-refractory
patient, one partial response in a Child–Pugh class B
patient, and six stable diseases were observed. The disease
control rate was 30 %, median progression-free survival
(PFS) time was 4.3 months, and median survival time was
8.9 months [63]. NGR-hTNF was considered well toler-
ated, as no grade 3–4 treatment-related toxicities were
noted in this study. Similar results were observed in the
patients enrolled in the weekly cohort.
In metastatic CRC, NGR-hTNF, which was adminis-
tered to 33 patients after failure of standard therapy, was
well tolerated, and the median PFS and overall survival
were 2.5 and 13.1 months, respectively [64]. The disease
control rate was 39.4 %, including one partial response and
12 stable diseases. Based on these observations, it was
concluded that NGR-hTNF deserves further evaluation in
MPM, HCC, and CRC.
Combination studies A phase Ib study of NGR-hTNF in
combination with doxorubicin explored cytokine doses of
0.2, 0.4, 0.8, and 1.6 lg/m2 [65]. This combination was
well tolerated and a high disease control rate (73 %) was
achieved in a population of heavily chemotherapy pre-
treated patients, including anthracycline-pretreated
patients. No shedding of soluble TNF receptors occurred
with 0.8 lg/m2 or lower doses. The dose of 0.8 lg/m2
NGR-hTNF was selected for a phase II study of NGR-
hTNF in combination with doxorubicin in relapsed ovarian
cancer patients (n = 37) [66]. This study showed that the
drug combination has interesting clinical activity and a safe
toxicity profile: 23 % of patients had a partial response and
43 % had stable disease. Median PFS and overall survival
were 5 and 17 months, respectively. Considering that about
two thirds of these patients were platinum-refractory/
resistant, these results have been considered clinically
relevant. Furthermore, most commonly reported adverse
events were those typically expected when each drug is
given alone, suggesting that toxicity profiles of the two
drugs do not overlap or increase. Interestingly, a strong
association between baseline lymphocyte counts and out-
comes was observed, especially in refractory/resistant
subsets [66].
Another phase I trial of 0.8 lg/m2 of NGR-TNF in
combination with cisplatin, for patients with refractory
solid tumors, showed that this combination was also well
tolerated and induced objective response and disease sta-
bilization even in patients pre-treated with cisplatin [67].
Regarding combination studies, another phase II study
evaluated the safety of low-dose (0.8 lg/m2, optimal bio-
logical dose) and higher-dose (45 lg/m2, MTD) NGR-
hTNF in combination with fixed doses of oxaliplatin plus
capecitabine (XELOX) in CRC patients who had previ-
ously failed standard treatment [68]. Both doses of NGR-
hTNF were safely combined with XELOX in these
patients. However, a hint of activity was apparent only with
the lower dose. Remarkably, induction of sTNF-R1 and
sTNF-R2 was observed with the higher dose. Furthermore,
plasma levels of sTNF-Rs tended to correlate inversely
with progression-free intervals. These data are consistent
with preclinical studies in mice showing that a dose of
10 ng/mouse of NGR-mTNF, which is 100-fold higher
than the optimal biological dose (0.1 ng/mouse) leads to
sTNF-Rs shedding in circulation and, consequently, to
inhibition of its potential antitumor activity [42] (as dis-
cussed in the above sections; see also Fig. 1). It appears
therefore that NGR-hTNF has a complex dose-response
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curve also in humans, likely owing to the activation of
counter-regulatory mechanisms when moderate-high doses
are used.
High-dose NGR-hTNF in patients with refractory solid
tumors A recent phase I study was undertaken in 48
patients with refractory solid tumors to explore doses
(60–325 lg/m2) higher than the previously established
MTD (45 lg/m2), using a more protracted infusion length
(2 h) and mild paracetamol premedication [69]. The MTD
was not reached in this study and common related toxicity
included grade 1–2 chills (58 %). Changes in sTNF-R
shedding were not observed with the different doses, sug-
gesting a plateau effect in shedding kinetics. As best
response, 29 % of patients had stable disease. Lower levels
of sTNF-R2 and greater Ktrans values, by DCE-MRI, after
the first cycle, were associated with improved survival
[69]. These results suggest that NGR-hTNF can be safely
escalated to high doses. The authors concluded that, based
on the observed tolerability profile and biological effects,
further testing of doses higher than 200 lg/m2 of NGR-
hTNF combined with chemotherapy and comparison with a
low dose of 0.8 lg/m2 is warranted [69].
Ongoing phase III study Based on the encouraging results
obtained with low-dose NGR-hTNF in MPM patients, a
randomized, double-blind, phase III study of NGR-hTNF
plus best investigator’s choice (BIC) versus placebo
plus BIC in previously treated patients with advanced
MPM started in 2010 (http://www.clinicaltrialsfeeds.org/
clinical-trials/show/NCT01098266). The main objective of
this trial is to document the efficacy of low-dose weekly
NGR-hTNF in combination with BIC in advanced MPM
patients previously treated with a pemetrexed-based che-
motherapy regimen. The results obtained in the phase II
study in MPM and HCC patients enabled NGR-TNF to
be granted ‘Orphan Drug’ designation for these indications
in the EU and the USA (http://www.molmed.com/eng/
pipeline_arenegyr.asp).
2.3 Other NGR-Cytokine Fusion Products
NGR-peptides have also been used for delivering, in
addition to TNF, IFNc and IFN-a2a to the tumor neo-
vasculature. The rationale for this approach relies on the
observation that IFNc can inhibit tumor angiogenesis [70,
71] and augment the expression of MHC-I and II on
cancer and endothelial cells [72, 73]. Within tumor
stroma IFNc can induce cytokine and chemokine secre-
tion, including IP-10, an angiostatic protein and a che-
moattractant factor for lymphocytes and monocytes [71,
74]. Evidence has been obtained to suggest that IFNc
produced by tumor-infiltrating macrophages plays a role
in tumor blood vessel destruction [75]. Combined
treatment of endothelial cells with IFNc and TNF results
in synergistic cytotoxic effects, likely important for tumor
vasculature destruction [76]. In addition, IFNc induces
anti-proliferative and pro-apoptotic effects on many tumor
cell types and activate natural killer cells and macro-
phages to kill a variety of tumor cell targets [75]. IFNc is
also an important regulator of CD4? T-helper cells and is
the major physiological macrophage-activating factor [77,
78]. As a consequence of these effects on tumor vascu-
lature and on cells of the immune system, IFNc can
activate inflammatory/immune responses against estab-
lished tumors and inhibit tumor growth. Because of its
immunomodulatory and anticancer activities, IFNc has
been used as an anticancer drug in several clinical studies,
unfortunately with modest results [79, 80]. Attempts to
increase the response by increasing the dose or by repe-
ated injections often resulted in lower efficacy, likely due
to counter-regulatory mechanisms [81, 82]. Experiments
in murine models showed that targeted delivery of minute
amounts (picograms) of an IFNc-GCNGRC fusion prod-
uct (called IFNc-NGR) to tumor vasculature could be a
valuable strategy for uncoupling antitumor activity and
counter-regulatory mechanisms [83]. However, the dose-
response curve observed in animal models with this
conjugate was bell-shaped, suggesting that counter-regu-
latory mechanisms can still be activated with high-dose
IFNc-NGR. Furthermore, although the therapeutic effi-
cacy of this protein in animal models is greater than that
of IFNc, frequent administrations of IFNc-NGR result in
lower efficacy and tumor resistance [83]. Mechanistic
studies of tumor resistance to repeated treatments with
IFNc-NGR suggested a crucial role of indoleamine 2,3-
dioxygenase (IDO), an IFNc-inducible enzyme that may
down-regulate T cells by affecting local tryptophan
catabolism. Coadministration of IFNc-NGR with
1-methyltryptophan, an inhibitor of IDO, increased tumor
responses to multiple treatments in lymphoma, melanoma,
and fibrosarcoma models [84].
Other investigators showed that the anti-tumor activity
of IFNa2a can also be increased by coupling this protein
with an NGR peptide [85]. Studies performed in animal
models showed that the IFNa2a-NGR conjugate, but not
IFNa2a, accumulates and target tumor vessels [86–88].
Notably, a fusion protein consisting of the extracellular
domain of tissue factor (truncated tissue factor [tTF]) and
peptide GNGRAHA (tTF-NGR), but not untargeted tTF,
induced thrombosis of blood vessels in solid tumors in
mice [89]. Clinical application of low dosages of this tar-
geted coagulation factor revealed good tolerability and
decreased tumor perfusion. These observations further
highlight the utility of NGR peptides as targeting ligands in
patients.
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3 RGD-, isoDGR-, and RGR-Mediated Targeting
of Cytokines to Tumor Vasculature
Besides the NGR-cytokine fusion products, other peptide-
cytokine conjugates based on the RGD, isoDGR, or RGR
sequences have been developed. Their biochemical and
biological properties are described in the following
sections.
3.1 Cytokine Targeting via Peptides Containing
the RGD Motif
Peptides containing the RGD sequence have been widely
used, like NGR-peptides, as ligands for the delivery of a
variety of drugs, nanoparticles, and diagnostic agents to
tumors, including cytokines [90–93]. The RGD sequence
was originally discovered as a binding site of a number of
extracellular matrix, blood, and cell surface proteins for
integrins, a large class of ab heterodimeric membrane
receptors involved in cell adhesion [94, 95]. Various ab
heterodimers can be recognized by RGD, including avb1-,
avb3-, avb5-, avb6-, avb8-, a5b1-, a8b1-, and aIIbb3-
integrins [94, 96]. These integrins can be recognized in a
differential manner by different RGD peptides, as the
molecular scaffold in which RGD is inserted may contribute
to control its conformation and therefore its integrin-binding
affinity and specificity [97]. Thus, a variety of different
peptides with different binding properties, in the low nano-
molar and subnanomolar range, have been developed [97].
Interestingly, because the avb3 heterodimer is overexpres-
sed in the tumor vasculature, this receptor is an attractive
pharmacological target for ligand-directed delivery of
cytokines to tumor vessels [98, 99]. To assess this hypothe-
sis, TNF has been fused, by recombinant DNA technology, to
ACDCRGDCFCG, a peptide ligand of av integrins discov-
ered by in vivo panning of peptide-phage libraries in tumor-
bearing mice [4, 93]. Subnanogram doses of this conjugate,
but not of TNF, were sufficient to induce antitumor effects in
tumor-bearing mice when combined with melphalan, sug-
gesting that these integrins are indeed good targets for
cytokine delivery to tumors. Unfortunately, this peptide
contains four Cys residues. Thus, the trimeric RGD-TNF
fusion product was difficult to fold in a homogeneous manner
and, for this reason, NGR-TNF was preferred for clinical
development. However, intramuscular administration of
plasmid DNA encoding ACDCRGDCFCG–TNF or
CNGRCG-TNF, but not plasmids encoding TNF, inhibited
to a similar extent the growth of murine melanomas and
lymphomas implanted subcutaneously at sites distant from
the site of plasmid injection, suggesting that both fusion
products are valid for a gene therapy approach [100].
3.2 Cytokine Targeting via Peptides Containing
the isoDGR Motif
IsoDGR is a tripeptide sequence, closely related to RGD,
which was originally discovered in aged fibronectin, a
protein of the extracellular matrix that contains four NGR
sites [101]. This motif was later found to also represent an
important degradation product of NGR-drug conjugates.
The isoDGR sequence can arise in fibronectin and NGR-
peptides as a consequence of asparagine deamidation [101,
102]. Experimental evidence suggests that the NGR-to-i-
soDGR transition, which occurs spontaneously and in a
relatively short time in fibronectin fragments and in cyclic
NGR peptides (half life 4–5 h), can work as a biological
switch for the regulation of cell adhesion, isoDGR being an
integrin-recognition motif [101–103]. Biochemical and
functional studies have shown that NGR flanking residues
and molecular scaffold markedly contribute to peptide
stability [104]. Studies performed with synthetic peptides
showed that isoDGR, like RGD, can recognize RGD-
dependent integrins (such as avb3, avb5, avb6, avb8, and
a5b1) with different affinity and selectivity, depending on
the molecular scaffold in which isoDGR is inserted [104–
107]. Biochemical studies, NMR structure analysis and
avb3-docking experiments performed with a disulphide-
bridged CisoDGRC peptide showed that isoDGR can fit
into the RGD-binding pocket of this integrin, recapitulating
not only the canonical RGD/avb3 contacts but also
establishing additional polar interactions [108]. Interest-
ingly, a recent study showed that isoDGR, but not RGD, is
a pure integrin antagonist [109]. The structural and func-
tional similarity with RGD suggests that isoDGR can also
be exploited, like RGD, as a ligand for targeted delivery of
drugs, imaging agents, or other compounds to tumors.
Consistent with this, fluorescent nanoparticles coupled to a
cyclic CisoDGRC peptide could bind avb3-integrin and
colocalize with antibodies against this integrin in vessels of
human renal cell carcinoma [110]. Furthermore, extremely
low doses (1–10 pg) of a recombinant protein made up of
CisoDGRC fused to TNF induced anti-tumor effects in
tumor-bearing mice through specifically targeting TNF to
tumor sites (Curnis et al. [110]). Another peptide, con-
sisting of head-to-tail cyclized c(CGisoDGRG), recognizes
avb3 with very good selectivity after chemical conjugation
to human serum albumin via thiol group [111]. IsoDGR-
tagged albumin has been exploited for the preparation of
TNF-bearing gold nanoparticles that efficiently home to
tumors [111]. Colloidal gold is a well tolerated nanoma-
terial currently exploited for several applications in the
field of nanomedicine, including TNF delivery [112–115].
Notably, gold nanoparticles coated with both isoDGR-
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tagged albumin and TNF have improved anti-tumor
activity compared with TNF and gold-TNF nanoparticles
[111]. This suggests that other TNF-based nanoparticles
and polymer conjugates, which are currently being devel-
oped by different laboratories [115], might also be
improved by tagging with isoDGR peptides.
4 RGR-Mediated Targeting of Cytokines to Tumor
Vasculature
Another ligand that has been used for the delivery of
cytokines, such as TNF and IFNc, to the tumor vasculature
is the RGR peptide [116]. This peptide has also been
identified by phage display against pancreatic tumors and
been shown to specifically bind to highly angiogenic ves-
sels in murine insulinomas [116]. Studies in animal models
showed that recombinant TNF-RGR and IFNc-RGR
selectively home to tumors and are retained in the micro-
environment [117]. Interestingly, IFNc-RGR predomi-
nantly acted as an anti-vascular agent in RIP1-Tag5
transgenic mice, which express the SV40 Large T antigen
under control of the rat insulin gene promoter and develop
pancreatic neuroendocrine tumors over time. In contrast,
TNF-RGR (2 lg over 2 weeks) did not destroy angiogenic
vessels but instead induced a more regular and less leaky
vascular network with small vessel calibers and mural
stabilization, thus improving tumor perfusion. TNF-RGR
enhanced T-cell infiltration and overall survival, an effect
that was exclusively mediated by CD8? effector cells.
Vessel remodeling induced by TNF-RGR substantially
improved antitumor vaccination or adoptive T-cell therapy
[118]. These findings, and the observation that NGR-TNF
can also be exploited to enhance T-cell infiltration in tumor
tissues [45], suggest that vascular targeting with peptide-
TNF conjugates is a good strategy for improving
immunotherapy.
5 Conclusion
The results of preclinical and clinical studies performed so
far with peptide-cytokine conjugates suggest that the pep-
tide-based tumor vascular targeting approach is a viable
strategy for improving their therapeutic index, at least for
certain cytokines, such as TNF, IFNc, and IFNa2a.
Although the targeting approach is generally conceived to
permit administration of low, yet pharmacologically active,
doses of drugs in order to avoid toxic reactions, it is
becoming clear that this strategy has another inherent
advantage, i.e., the possibility to administer extremely low
doses that do not activate systemic counter-regulatory
mechanisms, which tend to block the potential therapeutic
effects of cytokines. This is made possible by the good
accessibility of the target (endothelial cells) and by the
high affinity for targeting receptors that can be achieved
with peptide-cytokine conjugates, likely owing to multiple
receptor interactions. In principle, the same goals can be
achieved with antibodies and, indeed, many studies have
demonstrated the utility of this class of targeting ligands for
cytokine delivery, including TNF and several other cyto-
kines [1, 2, 119]. However, the low molecular weight and
the poor immunogenicity observed with peptides may
represent an important advantage, particularly for therapies
that need prolonged and repeated treatments. Considering
the large number of tumor vasculature-homing peptides
discovered in the last decade [3, 120] and the promising
results obtained so far with the prototypic peptide-cytokine
conjugates described here, the development of other con-
jugates made with different peptides and synergistic cyto-
kines might lead to the development of new therapeutic
options for cancer patients.
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